206 related articles for article (PubMed ID: 17130581)
1. Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes.
Young DL; Ramanujan S; Kreuwel HT; Whiting CC; Gadkar KG; Shoda LK
Ann N Y Acad Sci; 2006 Oct; 1079():369-73. PubMed ID: 17130581
[TBL] [Abstract][Full Text] [Related]
2. CD3 antibody treatment stimulates the functional capability of regulatory T cells.
Chatenoud L
Novartis Found Symp; 2003; 252():279-86; discussion 286-90. PubMed ID: 14609225
[TBL] [Abstract][Full Text] [Related]
3. L11, a unique anti-CD43 monoclonal antibody, inhibits the adoptive transfer of diabetes and pancreatic islet, salivary gland, and lacrimal gland inflammation in NOD/scid mice.
Mikulowska A; Johnson GG; Berberian JM; Butcher EC; McEvoy LM; Michie SA
Cell Immunol; 1999 May; 194(1):112-7. PubMed ID: 10357887
[TBL] [Abstract][Full Text] [Related]
4. Transgenic expression of single-chain anti-CTLA-4 Fv on beta cells protects nonobese diabetic mice from autoimmune diabetes.
Shieh SJ; Chou FC; Yu PN; Lin WC; Chang DM; Roffler SR; Sytwu HK
J Immunol; 2009 Aug; 183(4):2277-85. PubMed ID: 19635924
[TBL] [Abstract][Full Text] [Related]
5. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes.
Silveira PA; Grey ST
Trends Endocrinol Metab; 2006; 17(4):128-35. PubMed ID: 16580840
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for the prevention and treatment of type 1 diabetes.
Goudy KS; Tisch R
Int Rev Immunol; 2005; 24(5-6):307-26. PubMed ID: 16318984
[TBL] [Abstract][Full Text] [Related]
8. On the pathogenicity of autoantigen-specific T-cell receptors.
Burton AR; Vincent E; Arnold PY; Lennon GP; Smeltzer M; Li CS; Haskins K; Hutton J; Tisch RM; Sercarz EE; Santamaria P; Workman CJ; Vignali DA
Diabetes; 2008 May; 57(5):1321-30. PubMed ID: 18299317
[TBL] [Abstract][Full Text] [Related]
9. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation.
Khadra A; Santamaria P; Edelstein-Keshet L
J Theor Biol; 2009 Jan; 256(1):126-41. PubMed ID: 18950644
[TBL] [Abstract][Full Text] [Related]
10. Autoimmunity triggers in the NOD mouse: a role for natural auto-antibody reactivities in type 1 diabetes.
Côrte-Real J; Duarte N; Tavares L; Penha-Gonçalves C
Ann N Y Acad Sci; 2009 Sep; 1173():442-8. PubMed ID: 19758184
[TBL] [Abstract][Full Text] [Related]
11. Patients with chronic pancreatitis have islet progenitor cells in their ducts, but reversal of overt diabetes in NOD mice by anti-CD3 shows no evidence for islet regeneration.
Phillips JM; O'Reilly L; Bland C; Foulis AK; Cooke A
Diabetes; 2007 Mar; 56(3):634-40. PubMed ID: 17327430
[TBL] [Abstract][Full Text] [Related]
12. Transfusion of apoptotic beta-cells induces immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice.
Xia CQ; Peng R; Qiu Y; Annamalai M; Gordon D; Clare-Salzler MJ
Diabetes; 2007 Aug; 56(8):2116-23. PubMed ID: 17496235
[TBL] [Abstract][Full Text] [Related]
13. CD8(+) T cells specific for beta cells encounter their cognate antigens in the islets of NOD mice.
Pang S; Zhang L; Wang H; Yi Z; Li L; Gao L; Zhao J; Tisch R; Katz JD; Wang B
Eur J Immunol; 2009 Oct; 39(10):2716-24. PubMed ID: 19658094
[TBL] [Abstract][Full Text] [Related]
14. CD8+ T cells in type 1 diabetes.
Tsai S; Shameli A; Santamaria P
Adv Immunol; 2008; 100():79-124. PubMed ID: 19111164
[TBL] [Abstract][Full Text] [Related]
15. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.
You S; Leforban B; Garcia C; Bach JF; Bluestone JA; Chatenoud L
Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6335-40. PubMed ID: 17389382
[TBL] [Abstract][Full Text] [Related]
16. Peptide-pulsed immature dendritic cells reduce response to beta cell target antigens and protect NOD recipients from type I diabetes.
Lo J; Peng RH; Barker T; Xia CQ; Clare-Salzler MJ
Ann N Y Acad Sci; 2006 Oct; 1079():153-6. PubMed ID: 17130547
[TBL] [Abstract][Full Text] [Related]
17. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
[TBL] [Abstract][Full Text] [Related]
18. Clinical studies. Trying to reset the clock on type 1 diabetes.
Couzin-Frankel J
Science; 2011 Aug; 333(6044):819-21. PubMed ID: 21835995
[No Abstract] [Full Text] [Related]
19. Transient chemokine receptor blockade does not prevent, but may accelerate type 1 diabetes in prediabetic NOD mice.
Seifarth C; Mack M; Steinlicht S; Hahn EG; Lohmann T
Horm Metab Res; 2006 Mar; 38(3):167-71. PubMed ID: 16673207
[TBL] [Abstract][Full Text] [Related]
20. beta cell-specific CD4+ T cell clonotypes in peripheral blood and the pancreatic islets are distinct.
Li L; He Q; Garland A; Yi Z; Aybar LT; Kepler TB; Frelinger JA; Wang B; Tisch R
J Immunol; 2009 Dec; 183(11):7585-91. PubMed ID: 19917704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
